Fyarro 100 mg lyophilized powder for injectable suspension Images
Generic Name: sirolimus protein-bound
This medication has been identified as Fyarro 100 mg lyophilized powder for injectable suspension. It is supplied by Aadi Bioscience.
Fyarro is used in the treatment of Malignant Perivascular Epithelioid Cell Tumor and belongs to the drug class mTOR inhibitors. Fyarro 100 mg lyophilized powder for injectable suspension is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Fyarro
- Generic Name
- sirolimus protein-bound
- Strength
- 100 mg lyophilized powder for injectable suspension
- Availability
- Prescription only
- Drug Class
- MTOR inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Aadi Bioscience
- National Drug Code (NDC)
- 80803-0153
See also:
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Afinitor Disperz
Afinitor Disperz is used for subependymal giant cell astrocytoma, tuberous sclerosis complex
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Hyftor
Hyftor (sirolimus topical gel) is used for facial angiofibroma associated with tuberous sclerosis ...
Rapamune
Rapamune (sirolimus) is used to prevent rejection in people who have received a kidney transplant ...
Torisel
Torisel is used to treat cancer of the kidneys, also called renal cell carcinoma. Learn about side ...
Zortress
Zortress (everolimus) is used to prevent organ rejection in adult kidney transplant recipients ...
Sirolimus topical
Sirolimus topical is used for angiofibroma, tuberous sclerosis complex
More about Fyarro (sirolimus protein-bound)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: mTOR inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.